Search - tctmd.com

Displaying 141 - 160 of 243

Sort: Relevancy | Date

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

News Daily News

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

Michael O'Riordan

July 13, 2020

News Conference News ACC 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

Michael O'Riordan

March 28, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

Earlier, Longer Interventions Proposed for Optimal Population LDL Cholesterol

Yael L. Maxwell

January 28, 2020

News Daily News

Coconut Oil Ups LDL Cholesterol Compared With Other Fats: Meta-analysis

Yael L. Maxwell

January 16, 2020

News Daily News

Higher Chili Pepper Consumption Linked to Fewer CVD Deaths

L.A. McKeown

December 17, 2019

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

Todd Neale

November 17, 2019

News Daily News

Disparate US Trends in Early CVD Deaths Speak to Need for Targeted Prevention

Caitlin E. Cox

October 21, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

L.A. McKeown

September 16, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Features

Wearables Under the Microscope: How New Tech Will Disrupt Patient-Physician Dynamics

Marcus A. Banks

August 15, 2019

News Daily News

Ideal CV Health at Age 50 Foretells Lower Risk of Later Dementia

Marcus A. Banks

August 12, 2019

News Daily News

Hypertension During Pregnancy Increases Later CVD Risk by More Than 50%

Yael L. Maxwell

June 14, 2019

News Daily News

Risk Prediction Tool Shows Promise for Detecting Heart Failure Earlier

L.A. McKeown

May 13, 2019

News Daily News

High-Normal Glucose Challenge Tests in Pregnancy May Predict Future Risk of CV Events

L.A. McKeown

April 11, 2019

News Daily News

Poor Diet Responsible for 11 Million Deaths Annually, With CVD a Leading Cause

Michael O'Riordan

April 04, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

Advertisement

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Earlier, Longer Interventions Proposed for Optimal Population LDL Cholesterol

Coconut Oil Ups LDL Cholesterol Compared With Other Fats: Meta-analysis

Higher Chili Pepper Consumption Linked to Fewer CVD Deaths

Dapagliflozin Has Benefits Across Heart Failure Subgroups

Disparate US Trends in Early CVD Deaths Speak to Need for Targeted Prevention

Recurrent Events Common Among Young Patients With CAD

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Wearables Under the Microscope: How New Tech Will Disrupt Patient-Physician Dynamics

Ideal CV Health at Age 50 Foretells Lower Risk of Later Dementia

Hypertension During Pregnancy Increases Later CVD Risk by More Than 50%

Risk Prediction Tool Shows Promise for Detecting Heart Failure Earlier

High-Normal Glucose Challenge Tests in Pregnancy May Predict Future Risk of CV Events

Poor Diet Responsible for 11 Million Deaths Annually, With CVD a Leading Cause

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content